[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fuchs-endothelial-corneal-dystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fuchs-endothelial-corneal-dystrophy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,72,106,128,154,180,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100582138","prognosis-of-posterior-lamellar-keratoplasty-100582138",false,"NCT06859411","Prognosis of Posterior Lamellar Keratoplasty","Prognosis of Posterior Lamellar Keratoplasty: an Observational Cohort Study","CORNEACOHORT","Inclusion Criteria:\n\n* patients who received a posterior lamellar keratoplasty in Metz-Thionville Regional Hospital between 2012 and 2030\n\nExclusion Criteria:\n\n* patients refusing to take part in the study","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Over the past decade, the management of Fuchs' endothelial corneal dystrophy (FECD) and pseudophakic bullous keratopathy (PBK) has been revolutionized by the development of posterior lamellar keratoplasty techniques: DSAEK and DMEK.\n\nDSAEK (Descemet Stripping Automated Endothelial Keratoplasty) involves replacing the patient's endothelium and pathological descemetum with a descemetic endothelial graft combined with a thin stromal lamella. The endothelial density of the grafts is generally greater than 2,400 cells\u002Fmm². Depending on the grafting center and tissue bank, grafts may be either pre-cut in the tissue bank or cut on the operating table by the surgeon himself.\n\nThe donor graft is placed on an artificial anterior chamber, and automated microkeratome cutting produces grafts with an average thickness of 100 to 200µm, sometimes less than 100um (known as UT-DSAEK or ultra-thin DSAEK).\n\nDMEK (Descemet Membrane Endothelial Keratoplasty) is a strictly endothelium and Descemet's membrane graft, as close as possible to the original anatomy of the cornea. The graft is dissected manually either in a tissue bank (pre-cut grafts) or on the operating table by the surgeon. The thickness of the graft is between 15 and 18 microns.\n\nThe primary objective of this observational cohort is to compare the evolution of visual acuity after DMEK, DSAEK or UT-DSAEK transplantation.\n\nSecondary objectives are to compare the evolution of endothelial cell density, corneal thickness and early and late post-operative complications, and to identify factors predictive of these different endpoints.",[25,26],"Fuchs' Endothelial Corneal Dystrophy","Pseudophakic Bullous Keratopathy",[28,29,30,31],"posterior lamellar keratoplasty","cornea","DMEK","DSAEK","RECRUITING","2026-06-20",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2024-06-01",{"date":40,"type":21},"2040-01-01",{"name":42,"class":43},"Centre Hospitalier Régional Metz-Thionville","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100634386","effect-of-descemet-membrane-polishing-in-fuchs-endothelial-corneal-dystrophy-100634386","NCT07539012","Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy","Fuchs Polishin","Inclusion Criteria:\n\n* Patient affiliated with or entitled to a social security scheme\n* Patient scheduled for endothelial keratoplasty for Fuchs endothelial corneal dystrophy\n* Patient having received full information and having provided written informed consent\n\nExclusion Criteria:\n\n* Pregnant women\n* Adults under legal protection (guardianship\u002Fcuratorship) or unable to provide informed consent",{"count":53,"type":21},20,"INTERVENTIONAL",[56],"NA","Fuchs endothelial corneal dystrophy (FECD) is the leading indication for corneal transplantation worldwide. It is characterized by the accumulation of guttae and progressive loss of corneal endothelial cells, leading to corneal edema and visual impairment. Endothelial keratoplasty remains the standard treatment; however, graft shortages have driven the development of cell-based therapies involving the injection of cultured endothelial cells. A key unresolved issue is whether removal of the pathological endothelium prior to injection improves cell adhesion. Clinical data are limited and sometimes contradictory, particularly regarding endothelial polishing. The actual effectiveness of this procedure in removing guttae and enhancing the survival of injected cells remains uncertain. Therefore, an in vivo clinical evaluation is required to assess its impact on guttae removal.",[59],"Fuchs Endothelial Corneal Dystrophy",[59,61,62],"Corneal endothelial polishing","Ophtalmic therapeutics","2026-05-21",{"date":65,"type":36},"2026-05-26",{"date":63,"type":36},{"date":68,"type":21},"2027-03-01",{"name":70,"class":43},"Centre Hospitalier Universitaire de Saint Etienne",5,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":54,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":44},"100626898","partial-range-of-field-iols-in-dmek-enabled-procedures-100626898","NCT07441616","Partial Range Of Field IOLs in DMEK-Enabled Procedures","A Feasibility Study Evaluating Visual Outcomes of Extended Partial Range of Field Refractive Intraocular Lenses in Patients Undergoing Combined Cataract Surgery and Descemet Membrane Endothelial Keratoplasty (Triple DMEK)","PROFIDE","Inclusion Criteria:\n\n* Patients with bilateral cataract grade greater than II, according to the Lens Opacities Classification System III (LOCS III) , combined with FECD displaying clinical or subclinical corneal edema or displaying visual disturbing guttae with at least Krachmer grade 3\n* Patients aged between 40 and 90 years\n* Capacity to read and to understand the study information and to provide informed consent, as well as Patient Reported Spectacle Independence Questionnaire (PRSIQ) and Patient Reported Visual Symptom Questionnaire (PRVSQ)\n* Patients willing and capable to attend the 6-month follow-up appointment\n\nExclusion Criteria:\n\n* history of ocular surgery\n* corneal scars\n* macular disease revealed by pre-surgical macular Optical Coherence Tomography (OCT),\n* opticopathy\n* glaucoma with reduced sensitivity of visual field\n* uveitis\n* amblyopia\n* axial length \\\u003C22mm or \\>25mm,\n* scotopic pupil size \\>5mm,\n* central corneal thickness \\>700microns,\n* corneal astigmatism \\>1 diopters (D) on biometry\n* irregular astigmatism (RMS HOA 3mm pupil \\>0.3)\n* angle kappa \\>0.3mm ((chord µ measured with Pentacam HR; Oculus, Wetzlar, Germany)","40 Years","90 Years",{"count":83,"type":21},10,[56],"Study Overview\n\nThis study aims to evaluate the visual outcomes, quality of vision, and patient satisfaction after receiving an extended range PRoF intraocular lens (IOL) during triple Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. This surgery is typically performed to treat patients with both corneal endothelial dysfunction and cataracts. By testing a newer IOL, the PureSee™ extended PRoF IOL, this study hopes to improve the way ophthalmologists plan surgeries and select IOLs for these patients, ultimately helping surgeons optimize the results and expand the options available for people undergoing this procedure.\n\nPurpose of the Study\n\nThe goal of this study is to evaluate how well the PureSee™ IOL works in terms of intermediate visual acuity (how well participants can see things at an arm's length). The investigators will also measure the quality of vision, satisfaction, and whether participants need glasses after surgery.\n\nThe investigators have set the following goals for this study:\n\nPrimary Goal:\n\nTo measure how well patients can see intermediate distances (uncorrected intermediate visual acuity, or UIVA) after receiving the PureSee™ IOL during triple DMEK surgery.\n\nSecondary Goals:\n\nTo understand how independent patients are from glasses after surgery.\n\nTo measure patients' uncorrected and best-corrected visual acuity (sharpness of vision) at distance, intermediate, and near vision after surgery.\n\nTo evaluate the uncorrected defocus curve (how the vision of participants changes when focusing at different distances).\n\nTo measure contrast sensitivity (how well participants can see in low-light conditions or with subtle contrasts).\n\nWho Can Join This Study?\n\nTo participate in this study, participants need to:\n\nBe undergoing triple DMEK surgery for endothelial dysfunction and cataract at the time of enrollment.\n\nBe eligible to receive an extended range of vision IOL as part of the procedure.\n\nThis study is looking for patients who are interested in understanding how new IOL technology might improve their postoperative vision quality and reduce their dependence on glasses.\n\nWhat Will Happen During the Study?\n\nParticipants will have their visual outcomes and satisfaction measured at specific times following surgery. This includes:\n\nTesting uncorrected and best-corrected visual acuity at several distances (distance, intermediate, and near).\n\nCompleting a survey about how satisfied they are with their vision and how often they need glasses or contact lenses.\n\nUndergoing testing to measure contrast sensitivity (how well participants can see in low-light conditions).\n\nWhy Is This Study Important?\n\nThe results of this study will help doctors make better decisions about which IOLs to use during triple DMEK surgery. By evaluating the PureSee™ extended PRoF IOL, the investigators hope to expand options for patients and potentially improve visual outcomes and postoperative satisfaction. Ultimately, this study could help improve the quality of life for patients who have both cataracts and endothelial dysfunction.\n\nStudy Duration\n\nParticipants can expect to undergo their last assessment 6 months post-surgery to track their progress.",[87,59],"Cataract",[89,90,91,92,93,94,95],"dmek","triple","endothelial keratoplasty","fuchs","cataract","edof iol","partial range of field iol","NOT_YET_RECRUITING","2026-02-23",{"date":99,"type":36},"2026-03-02",{"date":101,"type":21},"2026-03",{"date":103,"type":21},"2028-02",{"name":105,"class":43},"Universitair Ziekenhuis Brussel",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":54,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100621684","influence-of-supine-positioning-on-the-outcomes-after-descemet-membrane-endothelial-keratoplasty-dmek-100621684","NCT07373821","Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK)","SUPINE","Inclusion Criteria:\n\nFuchs Endothelial Corneal Dystrophy Bullous Keratopathy\n\nExclusion Criteria:\n\nComorbidities preventing supine positioning",{"count":114,"type":21},102,[56],"The goal of this clinical trial is to learn if a longer period of lying on the back after corneal transplant surgery (Descemet Membrane Endothelial Keratoplasty, DMEK) helps the transplant stick better in the eye. It will also learn about side effects, such as back pain.\n\nThe main questions it aims to answer are:\n\n* Does lying on the back for 5 days reduce the size of transplant detachment compared to lying on the back for only 1 day?\n* Do participants who lie on their back longer need fewer additional procedures (rebubbling)?\n* What symptoms or problems do participants experience with short vs. long back positioning?\n\nResearchers will compare two groups:\n\n* 1 day of back positioning\n* 5 days of back positioning\n\nParticipants will:\n\n* Be randomly assigned to one of the two positioning groups\n* Wear a movement sensor that records head position\n* Have their eyes checked regularly with vision tests and imaging (AS-OCT)\n* Answer questions about their vision and comfort\n* Keep a diary of any positioning-related complaints, such as back pain",[59,118],"Descemet Membrane Endothelial Keratoplasty (DMEK)","2026-01-23",{"date":121,"type":36},"2026-01-28",{"date":123,"type":36},"2025-10-02",{"date":125,"type":21},"2027-03",{"name":127,"class":43},"University Hospital Heidelberg",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":54,"phases":138,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100594841","phase-2-dt-168-in-keratoplasty-patients-with-fuchs-endothelial-corneal-dystrophy-100594841","NCT07024693","DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy","A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty","Inclusion Criteria:\n\n* Participant is scheduled to undergo a keratoplasty for management of FECD independent of this study.\n* ≥30 years of age (inclusive).\n* Documented diagnosis of FECD in the study eligible eye.\n* Confirmation of positive TCF4 allele 18.1 CTG expansion in at least one allele.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Any ocular or medical condition in the study eligible eye which is clinically significant or would confound study results or data interpretation.\n* Any clinically significant medical, nonmedical, and psychiatric disorders that could put the participant at higher risk for participation in the study, impair the participant's ability to participate in the study, or interfere with interpretation of the participant's study results, in the opinion of the investigator.\n* Concurrent or anticipated need for treatment for FECD, eg, Muro 128 (2% or 5%) during the course of the study in the study eye. Provided the subject undergoes a washout of Muro drops for at least 24 hours prior to the Baseline Visit, they will not be excluded.\n* Concurrent or anticipated use of topical corticosteroids in the study eye.\n* Concurrent use with Rhopressa®, Rocklatan®, or any other ocular Rho Kinase inhibitor.\n* Known contraindication, allergy, or hypersensitivity to any of the treatments, anesthetics, or diagnostic agents or components thereof which may be used during the study.\n* Use of contact lenses in the study eye within 7 days prior to the Baseline Visit or planned use during the study.\n* Recent (within 30 days of the Screening Visit) or ongoing participation in any other investigational interventional clinical study.\n* Female participant is pregnant, planning a pregnancy, or breast-feeding.\n* Participant is unwilling to comply with the contraceptive requirements, as per protocol.","30 Years",{"count":137,"type":21},28,[139],"PHASE2","The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.",[59,142],"Fuchs","2025-12-24",{"date":145,"type":36},"2025-12-29",{"date":147,"type":36},"2025-07-30",{"date":149,"type":21},"2026-12",{"name":151,"class":152},"Design Therapeutics, Inc.","INDUSTRY",2,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":162,"targetDuration":164,"studyType":22,"phases":4,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":178,"locationsCount":44},"100613346","success-score-validation-in-fuchs-dystrophy-100613346","NCT07265388","SUCCESS Score Validation in Fuchs Dystrophy","Validation and Extension of the SUCCESS Score for Fuchs Dystrophy After Cataract Surgery","SUCCESS","Inclusion Criteria:\n\n* Adults aged ≥40 years.\n* Clinical diagnosis of Fuchs endothelial corneal dystrophy (FECD) grade ≥2 on the modified Krachmer scale.\n* Presence of visually significant cataract requiring phacoemulsification surgery.\n* Ability to provide informed consent and comply with study procedures.\n* Availability of preoperative Scheimpflug tomography and corneal densitometry measurements.\n\nExclusion Criteria:\n\n* Epithelial or stromal edema precluding reliable corneal imaging.\n* Previous ocular surgery (including corneal or intraocular procedures).\n* Corneal trauma, infection, or inflammation affecting endothelial integrity.\n* Coexisting ocular pathologies that could confound postoperative assessment (e.g., advanced glaucoma, macular degeneration).",{"count":163,"type":21},250,"5 Years","This prospective multicenter diagnostic study aims to externally validate and extend the SUCCESS Score for predicting the need for endothelial keratoplasty after cataract surgery in patients with Fuchs endothelial corneal dystrophy (FECD). The model's performance and clinical utility are assessed using discrimination, calibration, and reclassification metrics.",[59],[59,168,91,169,170,171],"Cataract Surgery","Diagnostic Accuracy","Prognostic Validation","Predictive Modeling","2025-11-24",{"date":174,"type":36},"2025-12-04",{"date":176,"type":36},"2020-06-01",{"date":149,"type":21},{"name":179,"class":43},"Instituto Ramón y Cajal de Investigación Sanitaria",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":54,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":44},"100396298","phase-2-targeting-reactive-oxygen-species-production-as-a-novel-therapeutic-in-fuchs-endothelial-corneal-dystrophy-100396298","NCT04440280","Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy","Inclusion Criteria:\n\n1. Male or female ≥21 years of age at time of surgical evaluation.\n2. Diagnosis of advanced FECD and visually significant cataract\n3. Indication for DMEK (Descemet Membrane Endothelial Keratoplasty) with concurrent cataract surgery\n4. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n5. Willingness and ability to adhere to medication regimen\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n2. History of prior intraocular surgery in study eye including cataract, glaucoma and\u002For retina surgery\n3. History of other corneal diseases, such as severe dry eye, corneal scars, pseudophakic bullous keratopathy, corneal degenerations, corneal infections\n4. Use of ocular prescription medications except for lubricants, hyperosmotic agents, or ocular hypotensive agents\n5. History of ocular surface infection within the past 30 days\n6. Use of systemic, inhalational, or topical N-Acetylcysteine within the past 30 days\n7. History of intolerance to topical N-Acetylcysteine\n8. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n\n   \\-","21 Years",{"count":188,"type":21},45,[139],"This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.",[59],[142,59,193,194,195,30],"oxidative stress","N-Acetylcysteine ophthalmic drops","Descemet Membrane Endothelial Keratoplasty","2025-09-23",{"date":198,"type":36},"2025-09-29",{"date":200,"type":36},"2020-09-16",{"date":202,"type":21},"2027-04-30",{"name":204,"class":43},"Massachusetts Eye and Ear Infirmary",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":44},"100590342","comparison-of-outcomes-between-femtosecond-laser-assisted-and-conventional-phacoemulsification-in-fuchs-endothelial-corneal-dystrophy-patients-with-cataracts-100590342","NCT06966167","Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With Cataracts","Inclusion Criteria:\n\n* Patients scheduled for cataract surgery\n* Age ≥40 years\n* Diagnosed with moderate to severe FECD (endothelial cell density \\\u003C1500 cells\u002Fmm²)\n\nExclusion Criteria:\n\n* History of prior intraocular surgery\n* Presence of ocular conditions other than FECD and cataracts (e.g., severe dry eye, corneal scarring, keratoconus, uveitis, uncontrolled glaucoma, vitreoretinal disease)\n* Requirement for additional intraocular procedures during the study period (excluding Nd:YAG posterior capsulotomy)",{"count":212,"type":21},120,"The goal of this observational study is to compare the mid- to long-term efficacy of femtosecond laser-assisted cataract surgery (FLACS) and conventional phacoemulsification surgery (CPS) in patients with moderate to severe Fuchs' endothelial corneal dystrophy (FECD) complicated by cataracts.\n\nThe main questions it aims to answer are:\n\nDoes FLACS lead to better preservation of corneal endothelial cells compared to CPS in patients with moderate to severe FECD? How do visual outcomes and corneal transparency compare between FLACS and CPS in this patient population?\n\nComparison Group:\n\nResearchers will compare patients undergoing FLACS with those undergoing CPS to evaluate differences in endothelial cell loss, corneal thickness, visual acuity, and corneal transparency.\n\nParticipants:\n\nAdults aged 40 years and older diagnosed with moderate to severe FECD (endothelial cell density \\\u003C1500 cells\u002Fmm²).\n\nPatients scheduled for cataract surgery at participating centers.\n\nParticipants will undergo:\n\nPreoperative evaluations, including visual acuity tests, corneal endothelial cell density assessment (central and five peripheral zones), corneal thickness, and corneal densitometry.\n\nSurgical intervention with either FLACS or CPS. Postoperative follow-ups at 1 day, 3 days, 1 week, 1 month, 3 months, 6 months, 1 year, and 2 years, including assessments of endothelial cell density, visual acuity, and corneal thickness.\n\nThis study aims to provide evidence-based recommendations for optimizing surgical strategies in high-risk patients with FECD and cataracts.",[59,87],[59,87,216,217],"Femtosecond Laser-Assisted Cataract Surgery","Conventional Phacoemulsification Surgery","2025-06-16",{"date":220,"type":36},"2025-06-17",{"date":222,"type":36},"2025-01-01",{"date":224,"type":21},"2030-01",{"name":226,"class":43},"Eye & ENT Hospital of Fudan University"]